Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First drug to treat spinal muscular atrophy gets FDA approval: Costly injectable shown to stall debilitating muscle-wasting effects of rare genetic disorder.

American journal of medical genetics. Part A - 1 Apr 2017

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Drug Approval
Share to Muscular Atrophy, Spinal
Share to Oligonucleotides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Survival of Motor Neuron 1 Protein

Share to Survival of Motor Neuron 2 Protein

Share to United States

Share to United States Food and Drug Administration

Source

Identifiers

PMID: 28328128
DOI: 10.1002/ajmg.a.38222

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First drug to treat spinal muscular atrophy gets FDA approval: Costly injectable shown to stall debilitating muscle-wasting effects of rare genetic disorder.PMID 28328128Read ↗

Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental TherapiesSemantic proximity Read ↗

Gene therapy for neuromuscular disorders: prospects and ethicsSemantic proximity Read ↗

Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA)Semantic proximity Read ↗

Current understanding of and emerging treatment options for spinal muscular atrophy with respiratory distress type 1 (SMARD1)Semantic proximity Read ↗

Spinal muscular atrophy: from rags to riches.Semantic proximity Read ↗

Emerging therapeutic strategies in muscular dystrophy: an updated review on pathogenesis and treatment advances.Semantic proximity Read ↗

Unmet Needs and Evolving Treatment for Limb Girdle Muscular DystrophiesSemantic proximity Read ↗

Perspectives on clinical trials in spinal muscular atrophy.Semantic proximity Read ↗

Towards a Cure: Emerging Therapeutic Advances for DMD, LGMD, and GNEM- Insights from Pre-Clinical and Clinical ResearchSemantic proximity Read ↗

Muscular dystrophy: new challenges and review of the current clinical trials.Semantic proximity Read ↗

Drug development progress in duchenne muscular dystrophySemantic proximity Read ↗

Neurology Care, Diagnostics, and Emerging Therapies of the Patient With Duchenne Muscular DystrophySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.